Matrix Pharmaceutical offers 3.6 million shares:
This article was originally published in Clinica
Matrix Pharmaceutical is offering 3.6 million shares at $13.25 each. Proceeds of $47.7 million are to be used for R&D, clinical testing and regulatory activities for Matrix' site-specific treatments for cancer and serious skin diseases. The company's most advanced products include the AccuSite gels and IntraDose injectable gel for delivering cancer therapeutics.